Renal news roundup from AKF

A new analysis by researchers from NYU Langone Health, the University of Glasgow and the Institute for Health Metrics and Evaluation highlights the alarming rise of chronic kidney disease (CKD), with the number of affected individuals worldwide increasing from 378 million in 1990...

A study in the JACC Advances found that 40% of people with type 2 diabetes have albuminuria, indicating a need for cardiovascular and renoprotective drugs. The study, involving 74,014 patients in Denmark, also highlighted that those with normoalbuminuria still face significant ca...

Laura Aponte Becerra, a nephrology fellow at Yale School of Medicine, says that individual treatment effect modeling did not improve acute kidney injury (AKI) progression, dialysis or mortality, but it may influence the way clinicians respond to targeted alerts, according to a pr...

A study in BMJ Medicine associated eating disorders with long-term physical and mental health risks, including diabetes, depression, kidney or liver failure, broken bones and premature death. Researchers said that while the risk was highest within the first year of diagnosis, it ...

The Centers for Medicare and Medicaid Services (CMS) has finalized a 2.2% reimbursement increase for dialysis providers for 2026. The agency also has discontinued the End-Stage Renal Disease Treatment Choices payment model that began in 2020. Modern Healthcare (tiered subscriptio...

Dr. Carney Taylor shares his experience of transitioning his nephrology practice in North Carolina to value-based care during the pandemic. This shift involved appointing physician leads, embedding renal care coordinators and adopting a nephrology-specific electronic health recor...

Jenifer and Ryan DeMarre have celebrated their 25th wedding anniversary by overcoming a major health challenge together. Ryan's kidney disease, diagnosed in 2009, reached a critical point this year, prompting Jenifer to test for compatibility. Discovering she was a perfect m...

The Food and Drug Administration (FDA) has approved Otsuka's Voyxact, the first drug of its kind for treating immunoglobulin A nephropathy (IgAN), a chronic autoimmune kidney disease that can lead to organ failure. "We are excited to make a new treatment option availabl...

Telix Pharmaceuticals said study data showed that use of its TLX250-CDx PET/CT imaging agent, marketed as Zircaix, could have changed the clinical management of nearly half of patients with indeterminate renal masses. The study, which will be presented at an upcoming conference, ...